Orphan Drugs

World Market Report

MCP-7443

EXECUTIVE ENGAGEMENTS

POOL

13394
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

1607
Interactions with Platform & by Email

PARTICIPANTS

402
Unique # Participated

VALIDATIONS

82
Responses Validated*

COMPANIES

18
Responses Validated*
* Login for a full stack data experience

DATE

OCT 2022

TABLES

202

PAGES

261

EDITION

16

PRICE

USD 5600

CODE

MCP-7443


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

RANK

(S/A/N/T)

%

VALIDATED RESEARCH *

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2022?

» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year

Amid the COVID-19 crisis, the global market for Orphan Drugs estimated at US$201.9 Billion in the year 2020, is projected to reach a revised size of US$545.4 Billion by 2027, growing at aCAGR of 15.3% over the period 2020-2027. Biologics, one of the segments analyzed in the report, is projected to record 15.8% CAGR and reach US$344.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Non-Biologics segment is readjusted to a revised 14.3% CAGR for the next 7-year period.
The Orphan Drugs market in the U.S. is estimated at US$59.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$94.7 Billion by the year 2027 trailing a CAGR of 14.6% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.5% and 12.9% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.7% CAGR.

SELECT PLAYERS

AbbVie Inc.; Actelion Pharmaceuticals Ltd.; Alexion Pharmaceuticals Inc.; Amgen Inc.; AstraZeneca Plc.; Bayer AG; Biogen Inc.; BioMarin Pharmaceutical Inc.; Boehringer Ingelheim GmbH; Bristol-Myers Squibb Company; Celgene Corp.; CEL-SCI Corporation; Concordia International Corp.; Eli Lilly and Company; F. Hoffmann-La Roche Ltd.; Genzyme Corp.,; Johnson & Johnson; Merck & Co. Inc.; Merck Serono SA; Novartis AG; Pfizer Inc.; Recordati S.p.A.; Sanofi SA; Shire Plc.; Vertex Pharmaceuticals

SEGMENTS

» Drug Type (Biologics, Non-Biologics) » Disease Type (Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy, Other Disease Types)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
A Prelude
Recent Market Activity
Increasing Adoption of Orphan Drugs by Manufacturers
The 1983 Orphan Drugs Act (ODA) Kickstarts the Industry
Major Orphan Drugs Legislations Worldwide
Orphan Drugs Market on a Rapid Growth Trajectory
Select Major Organizations Dealing with Rare Diseases in the US, Canada, and EU
Incentives for Orphan Drug Designation Products in the US, EU, and Japan
Market Challenges
Obstacles for Conducting Orphan Drug Research
Competition
Orphan Drugs Remain Strong in the Pharmaceutical Pipeline
Important Orphan Drugs in Pipeline
Orphan Drugs – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
AbbVie, Inc. (USA)
Actelion Pharmaceuticals Ltd. (Switzerland)
Alexion Pharmaceuticals, Inc. (USA)
Amgen, Inc. (USA)
AstraZeneca Plc. (UK)
Bayer AG (Germany)
Biogen Inc. (USA)
BioMarin Pharmaceutical Inc. (USA)
Boehringer Ingelheim GmbH (Germany)
Bristol-Myers Squibb Company (USA)
Celgene Corp. (USA)
CEL-SCI Corporation (USA)
Concordia International Corp. (Canada)
Eli Lilly and Company (USA)
F. Hoffmann-La Roche Ltd. (Switzerland)
Johnson & Johnson (USA)
Merck & Co., Inc. (USA)
Merck Serono International S.A. (Germany)
Merck Serono International S.A. (Germany)
Novartis AG (Switzerland)
Pfizer, Inc. (USA)
Recordati S.p.A. (Italy)
Orphan Europe (France)
Shire Plc. (Ireland)
Sanofi SA (France)
Genzyme Corp. (USA)
Vertex Pharmaceuticals (USA)
3. MARKET TRENDS & DRIVERS
Regulatory Incentives - A Push in the Right Direction
Growing Unmet Medical Needs - Fulfilling the Gap
Rising Incidence of Rare Forms of Cancer - Opportunities Galore
Select Orphan Drugs for Cancer
Rise in Incidence of Renal Cell Carcinoma
Unmet Needs in AML
Aging Population Offers Growth Potential
Pre-Symptomatic Screening to Expand Market Base
Asia’s Rising Awareness and Growing Population to Drive Sales
Drug Repurposing Provides Therapies for Rare Diseases
The Trend of Old Drugs Re-Surfacing as Orphan Drugs Surges
Interest of Major Pharmaceutical Firms Signal a Shift in Commercial Dynamics
Mergers and Acquisitions Drive Market Growth
Select Mergers & Acquisitions for Orphan Drugs as of the Year 2016
Growing Scrutiny over Skyrocketing Prices
Orphan Drugs with High Prices: 2016
Medical Advancements Foster Growth
Full Reimbursements Critical for Spurring Uptake of High-Priced Orphan Drugs
Regulators to Scrutinize Exorbitant Pricing of Ultra-Orphan Drugs
Strong Market Potential for Ultra-Orphan Drugs for Amyloid Light-chain Amyloidosis
Increasing Patient Engagement - The PAG Trend
Gene Therapy and Bioprocessing Preferred over Chronic Therapies
Companies Developing Gene Therapies
International Collaboration - The Way Forward
CNS Therapeutics to Gain Focus in the Orphan Drugs Market
Manufacturers Target Orphan Indications to Curtail Competition in Broader Indications
Manufacturers Use Orphan Disease to Target Larger Therapeutic Indications
Treating Autism - The Next Big Thing?
Sequencing Technology - The New Research Tool for Orphan Drugs
Innovations in Biotechnology - A Boon for Orphan Drug Research
Aging Gene Linked to Myeloma
Antibody with Potential to Treat Multiple Myeloma
Potential Treatment for Cystic Fibrosis Patients Infected with Mycobacterium abscessus
Genetic Variants to Improve Treatment of Non-small Cell Lung Cancer
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Orphan Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Non-Biologics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Non-Biologics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Hematology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Hematology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Cardiovascular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Cardiovascular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Endocrinology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Endocrinology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
World 15-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2021 & 2027
World Orphan Drugs Market Analysis of Annual Sales in US$ Million for Years 2012 through 2027
UNITED STATES
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2022 (E)
USA Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
USA Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
USA Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
USA 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027
CANADA
Canada Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
Canada Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Canada Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Canada 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027
JAPAN
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2022 (E)
Japan Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
Japan Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Japan Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Japan 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027
CHINA
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2022 (E)
China Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
China Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
China Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
China 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027
EUROPE
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2022 (E)
Europe Recent Past, Current & Future Analysis for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
Europe Historic Review for Orphan Drugs by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Orphan Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Europe 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027
FRANCE
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2022 (E)
France Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
France Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
France Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
France 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027
GERMANY
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2022 (E)
Germany Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
Germany Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Germany Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Germany 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027
ITALY
Italy Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
Italy Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Italy Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Italy 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027
UNITED KINGDOM
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2022 (E)
UK Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
UK Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
UK Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
UK 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
Rest of Europe Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of Europe Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of Europe 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027
ASIA-PACIFIC
Orphan Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2022 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
Asia-Pacific Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Asia-Pacific Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Asia-Pacific 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027
REST OF WORLD
Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Drug Type - Biologics and Non-Biologics - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Orphan Drugs by Drug Type - Biologics and Non-Biologics Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Orphan Drugs by Drug Type - Percentage Breakdown of Value Sales for Biologics and Non-Biologics for the Years 2012, 2021 & 2027
Rest of World Recent Past, Current & Future Analysis for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
Rest of World Historic Review for Orphan Drugs by Disease Type - Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
Rest of World 15-Year Perspective for Orphan Drugs by Disease Type - Percentage Breakdown of Value Sales for Oncology, Hematology, Neurology, Endocrinology, Cardiovascular, Respiratory, Immunotherapy and Other Disease Types for the Years 2012, 2021 & 2027

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com